Allarity Therapeutics, Inc. · NASDAQ:ALLR
Allarity Therapeutics — Corporate Update (February 2024)
16 slides from Allarity Therapeutics's corporate update, February 2024
Slide 1: A Gene Expression Based Biomarker For Predicting Response To Treatment
A Gene Expression Based Biomarker For Predicting Response To Treatment Thomas Jensen, CEO Feb 2024 Nasdaq: ALLR Copyright © 2023 Allarity Therapeutics. All rights reserved.
Slide 2: Legal Statement
Legal Statement This presentation is provided for informational purposes only and is subject to change. The information contained herein does not purport to be all-inclusive. The data contained herein is derived from various internal and external sources, and may rely upon assumptions, stated or oth
Slide 3: Our DRP Companion Diagnostics Platform
Our DRP® Companion Diagnostics Platform
Slide 4: DRP Supplements Conventional Biomarker Technology
DRP® Supplements Conventional Biomarker Technology Allarity’s DRP® develops predictive Conventional Biomarker Approaches work for biomarkers based upon complex some, but not all oncology drugs gene expression analysis Retrospectively & Broadly Applicable Prospectively Validated Artificial Gene Mutat
Slide 5: The DRP Platform Addresses the Complexity of Cancer
The DRP® Platform Addresses the Complexity of Cancer Cancer is Very Complex The Tumor Tells us What is Important “Systems biology” is used to analyze all genes (~25,000) Input is generated by taking drug testing data from cancer cell expressed in a cancer cell/tumor, without bias towards lines. Our
Slide 6: DRP CDx: Predicting a Cancer Patient's Drug Response
DRP® CDx: Predicting a Cancer Patient’s Drug Response Step 1 Step 2 Step 3 Patients’ biopsy samples Compare patients’ tumor gene Identify patients with high DRP® expression to DRP® signature score for a given drug MODERATE STRONG STRONG WEAK WEAK PATIENTS’ TUMORS PATIENTS’ TUMORS DRP + Allarity Ther
Slide 7: DRP Platform: Extensively Proven in Clinical Trials
DRP® Platform: Extensively Proven in 47 Clinical Trials PROSPECTIVE CLINICAL TRIALS – PHASE 2 DRP® Clinical Impact Cisplatin/LiPlaCis® Phase 2 study (n=37) completed – late-stage metastatic BC More than 50% Stenoparib Phase 2 study (n=30) underway – 3rd line ovarian cancer increase in response or ti
Slide 8: Publications of Clinical/Method Validation for Drug-Specific DRPs
Publications of Clinical/Method Validation for Drug-Specific DRP®’s 1. Chen J, et al. A 71-gene signature of TRAIL sensitivity in cancer cells. (October 25, 2011); Mol Cancer Ther, 10.1158/1535-7163. 2. Wang W, et al. Independent validation of a model using cell line chemosensitivity to predict resp
Slide 9: Revitalizing Former Big Pharma Therapeutics with Our DRP CDx
Revitalizing Former Big Pharma Therapeutics with Our DRP® CDx Classical Drug Development Allarity Approach Treat all of the patients Treat only patients sensitive to therapy Companion Low Average Diagnostics High Average Patient Benefit Patient Benefit PHASE 1/1b PHASE 2 PHASE 3 INDICATION RIGHTS Le
Slide 10: Prior validation example: Dovitinib
Prior validation example: Dovitinib Knudsen S, et al. PLOS ONE. 18(8): 2023
Slide 11: Dovitinib: A Unique Pan-Tyrosine Kinase Inhibitor (TKI)
Dovitinib: A Unique Pan-Tyrosine Kinase Inhibitor (TKI) Dovitinib Has Shown Therapeutic Equivalence to Sorafenib in Prior Phase 3 mRCC Study. It is no longer in clinical development, but was used to validate DRP • Pan-Tyrosine Kinase Inhibitor (TKI), small molecule, targeted inhibitor of FGFR, VEGFR
Slide 12: Dovitinib-DRP CDx Identifies Dovitinib-Responsive Patients
Dovitinib-DRP® CDx Identifies Dovitinib-Responsive Patients Dovitinib-DRP® CDx (58 mRNAs) Identified Patients with Overall Survival (OS) Benefit in Novartis Phase 3 in 3rd line RCC1 DRP selects survivors in dovitinib arm but not in sorafenib arm 1.0 Dov arm DRP+ (N=49, median 15.0 mo) • Dovitinib-DR
Slide 13: Ongoing Phase 2 Prospective trial: Stenoparib
Ongoing Phase 2 Prospective trial: Stenoparib
Slide 14: Stenoparib: A Unique Dual PARP and Tankyrase Inhibitor
Stenoparib: A Unique Dual PARP and Tankyrase Inhibitor Ongoing Phase 2 Monotherapy Study in 3rd Line Ovarian Cancer (OC) All patients screened with Stenoparib DRP to identify patients for inclusion • First-in-class small molecule targeted inhibitor of DNA damage repair Stenoparib (E7449) targets Wnt
Slide 15: Best percent change from baseline (target lesions)
At first interim analysis, all patients selected by DRP showed benefit (i.e. reduction in tumor size. This is better than what other PARP inhibitors have shown without DRP) Second interim analysis planned for H1 2024 at N=18 20 Best overall response Best percent change from baseline (target lesions)
Slide 16: Thomas Jensen CEO
Thomas Jensen CEO tjensen@allarity.com allarity.com
Allarity Therapeutics — Corporate Update (February 2024) on 6ix